Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.
about
Coartem: the journey to the clinicChlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malariaThe use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malariaIn vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central EthiopiaExperience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting.Improvements in access to malaria treatment in Tanzania following community, retail sector and health facility interventions -- a user perspectiveSustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective.Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionEvaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya.Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjectsTherapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern TanzaniaComparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic reviewIn vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia.Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malariaPresumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United StatesHealth providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania.Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight rangesTailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria.Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Northern Ethiopia.Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.Monitoring antimalarial safety and tolerability in clinical trials: a case study from UgandaCan Rapid Diagnostic Testing for Malaria Increase Adherence to Artemether-Lumefantrine?: A Randomized Controlled Trial in Uganda.Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in TanzaniaThe content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence.Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.Chloroquine resistance before and after its withdrawal in Kenya.Safety profile of Coartem: the evidence base.Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children.Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-AnalysisEfficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysisWorld Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility.The impact of packaging and messaging on adherence to malaria treatment: Evidence from a randomized controlled trial in Uganda
P2860
Q21034131-A621510E-0340-479C-96C8-2D6502631EDDQ21143739-8599330E-AF33-4E56-8B00-C91BB72E8029Q28478579-731B1489-0584-40AA-B32D-88EC4D6F2564Q28533253-446E6C77-3FA2-4AC6-B56B-7EA4B9F579DCQ30396779-72CDC364-4021-4662-A9D1-1F4A4081A989Q30396837-D92DFB0B-ED16-49EF-8355-F96D1CF93125Q30396940-6C5953BB-089C-42D2-A5C0-F5538F870DD7Q30397022-BBA890DA-3A01-478E-8BE3-D61C985D3E39Q33745061-CD88D413-1EB5-4955-8029-B70E89E09D21Q34020818-96921A42-E650-4C37-999C-372F617CEAC7Q34087271-85040AA9-5770-4D49-BC8B-827CCFACA25FQ34154423-0C78FCEA-8700-43E0-96B9-7FD58BA8B749Q34253706-20DB322E-9080-4648-A257-1B6A48D1FE3FQ35029488-BB611DA6-A2C4-44DC-AB21-43D4F35FB4CAQ35186075-5863ADB7-5569-4CDD-BED8-2C2F8DAA43EEQ35191375-05EB5E39-A86E-4417-8ADC-7F594A9EF1FFQ35245941-ECAD266B-B8FA-4D3F-BA4E-06B1E3288DB0Q35560610-3FA6F761-4EC3-4140-9A47-71D27207F165Q35833995-19581350-EF30-4881-8B84-E61870DA1C07Q35834482-16B52130-782F-4586-BCF7-B4CB8AF9212FQ35860066-BEEF096A-8A1C-4AE6-8AEF-F26EB4F03B66Q35919321-CC46372D-2E19-4299-A4DF-C0DEFBD7E96CQ36075783-5B0B6174-D275-4727-92EB-610FD31DE9A1Q36739784-A335A520-2C50-4F72-8C14-D36034D7F112Q36766577-D213E9A2-E2AD-45D2-B110-A96E74D90891Q36776118-159F9AC4-932A-408C-A141-7A342450BCF3Q36991071-FF217AED-512E-4A4F-9102-E85425D3827AQ37032498-5D7A7241-7899-4EE0-9A00-33BB7267536FQ37037149-080E436D-F817-4081-B1EB-749D43FB536EQ37223629-214DD95B-242E-4A65-AEA7-B572E3A0115AQ37383298-13F2E22C-D3D7-4392-BB23-0FE4B6C83751Q37388596-573F181C-FE4C-4F79-BFDA-29A828BC98AFQ37612067-C94FDEDB-0EAA-443C-B5CB-D94A3E64CC2EQ38544762-07543D36-4B2F-499E-9310-D121F1058F83Q38895510-672D763F-BFB1-4B8C-A9FA-E30D3EE64A0BQ41410017-2207D2FF-A14E-4324-9C9E-B9C0F3461DD7Q56909788-6482FBB4-2911-432A-8219-6ED5111260AB
P2860
Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and safety of the six ...... is of individual patient data.
@ast
Efficacy and safety of the six ...... is of individual patient data.
@en
type
label
Efficacy and safety of the six ...... is of individual patient data.
@ast
Efficacy and safety of the six ...... is of individual patient data.
@en
prefLabel
Efficacy and safety of the six ...... is of individual patient data.
@ast
Efficacy and safety of the six ...... is of individual patient data.
@en
P2093
P50
P1476
Efficacy and safety of the six ...... sis of individual patient data
@en
P2093
Catherine Falade
Edgar A Mueller
Kim Andriano
Patricia Ibarra De Palacios
Philip Hunt
Zul Premji
P304
P356
10.4269/AJTMH.2006.74.991
P407
P577
2006-06-01T00:00:00Z